Inflammatory Signal Inhibitors for COVID-19 (MATIS)
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The Multi-arm trial of Inflammatory Signal Inhibitors for COVID-19 (MATIS) study is a
two-stage, open-label, randomised controlled trial assessing the efficacy of ruxolitinib
(RUX) and fostamatinib (FOS) individually, compared to standard of care in the treatment of
COVID-19 pneumonia. The primary outcome is the proportion of hospitalised patients
progressing from mild or moderate to severe COVID-19 pneumonia. Patients are treated for 14
days and will receive follow-up assessment at 7, 14 and 28 days after the first study dose.
Patients with mild or moderate COVID-19 pneumonia will be recruited. Initially, n=171 (57 per
arm) patients will be recruited in Stage 1. Following interim analysis to assess the efficacy
and safety of the treatments, approximately n=285 (95 per arm) will be recruited during Stage
2.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Imperial College London
Collaborators:
Imperial College Healthcare NHS Trust Novartis Rigel Pharmaceuticals